Gene Regulation by Thiazolidinediones
- Registration Number
- NCT00567593
- Lead Sponsor
- James Lewis
- Brief Summary
The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon
- Detailed Description
The primary aim of the study is to examine the effect of rosiglitazone (Avandia) on gene regulation in colonic epithelium in the absence of pathologic acute and chronic intestinal inflammation. The secondary aims are to determine the effect of rosiglitazone (Avandia) therapy on T cell activation and cytokine expression in the absence of pathologic acute and chronic intestinal inflammation.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- Capable of giving informed consent
- Agrees to use a barrier method of birth control for the duration of the study
Exclusion Criteria
- History of inflammatory bowel disease
- Has taken prescription or over the counter medications in the two weeks prior to enrollment
- History of diabetes, heart failure, angina, hypertension, coronary heart disease, cancer, bleeding disorder, HIV, AIDS
- Fasting LDL >160 mg/dl
- History of smoking in the year prior to enrollment
- Pregnant or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Rosiglitazone Rosiglitazone Rosiglitazone; 8mg tablet once a day for 14 days
- Primary Outcome Measures
Name Time Method PDK4 mRNA 14 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Pennsylvania Clinical and Translational Research Center
🇺🇸Philadelphia, Pennsylvania, United States